Mechanopharmacology of Rho-kinase antagonism in airway smooth muscle and potential new therapy for asthma

Pharmacol Res. 2020 Sep:159:104995. doi: 10.1016/j.phrs.2020.104995. Epub 2020 Jun 10.

Abstract

The principle of mechanopharmacology of airway smooth muscle (ASM) is based on the premise that physical agitation, such as pressure oscillation applied to an airway, is able to induce bronchodilation by reducing contractility and softening the cytoskeleton of ASM. Although the underlying mechanism is not entirely clear, there is evidence to suggest that large-amplitude stretches are able to disrupt the actomyosin interaction in the crossbridge cycle and weaken the cytoskeleton in ASM cells. Rho-kinase is known to enhance force generation and strengthen structural integrity of the cytoskeleton during smooth muscle activation and plays a key role in the maintenance of force during prolonged muscle contractions. Synergy in relaxation has been observed when the muscle is subject to oscillatory length change while Rho-kinase is pharmacologically inhibited. In this review, inhibition of Rho-kinase coupled to therapeutic pressure oscillation applied to the airways is explored as a combination treatment for asthma.

Keywords: Bronchodilation; Contractility; Cytoskeleton; Mechanical oscillation; Passive stiffness; Synergy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / enzymology
  • Asthma / physiopathology
  • Bronchoconstriction / drug effects*
  • Bronchodilator Agents / therapeutic use*
  • Cytoskeleton / drug effects
  • Cytoskeleton / enzymology
  • Humans
  • Lung / drug effects*
  • Lung / enzymology
  • Lung / physiopathology
  • Mechanotransduction, Cellular / drug effects*
  • Molecular Targeted Therapy
  • Muscle, Smooth / drug effects*
  • Muscle, Smooth / enzymology
  • Muscle, Smooth / physiopathology
  • Protein Kinase Inhibitors / therapeutic use*
  • rho-Associated Kinases / antagonists & inhibitors*
  • rho-Associated Kinases / metabolism

Substances

  • Anti-Asthmatic Agents
  • Bronchodilator Agents
  • Protein Kinase Inhibitors
  • rho-Associated Kinases

Grants and funding